Enzymatica has appointed Katja Margell as Director of Investor Relations & Corporate Affairs. She will take up the role on 1 November 2026, with responsibility for investor relations, corporate communications, public affairs and stakeholder relations.
The appointment is part of Enzymatica’s efforts to build the team for its next phase of development. The role also encompasses policy matters and strategic engagement with medical opinion leaders, patient and consumer organizations, and stakeholders in sport and health.
A key part of the role will be to raise awareness of Enzymatica and ColdZyme and make the company’s scientific evidence and technology more accessible to wider audiences. This work will help build trust among priority stakeholder groups and support the company’s commercial and international ambitions.
“Enzymatica has world-class clinical evidence within the cold treatment category. We are now stepping up our efforts to communicate its relevance and significance to wider audiences. With Katja Margell, we strengthen our ability to reach the capital markets, medical opinion leaders, partners and other key stakeholders. Her experience in life sciences, strategic communications and investor relations will be important as we take a more active and proactive approach to our communications,” says Sana Alajmovic, CEO of Enzymatica.
Katja Margell joins from Duni Group, where she served as Director of Investor Relations and Communications. She previously led corporate communications at Hansa Biopharma and held senior communications roles at SEB. She also has extensive experience advising life science companies on strategic communications and capital markets matters.
“The common thread throughout my career has been making innovations understandable, relevant and capable of creating value. Enzymatica has an exciting scientific platform and a clear ambition to reach more people. I look forward to raising awareness of Enzymatica and ColdZyme and broadening engagement with the capital markets, medical opinion leaders and stakeholders in sport and health,” says Katja Margell.
For more information, please contact:
Sana Alajmovic, CEO, Enzymatica AB
E-mail: sana.alajmovic@enzymatica.com
Facts ColdZyme®
ColdZyme is a clinically documented medical device mouth spray for the common cold and cold-like symptoms and is certified under the EU Medical Device Regulation (MDR), Class III. The product was recently named best in test among cold sprays by the independent Swedish consumer guide Bäst-i-Test.se. Read more at www.coldzyme.se.
About Enzymatica
Enzymatica AB is a Swedish life science company that develops scientifically documented solutions for the treatment and relief of upper respiratory infections and related symptoms, based on a unique barrier technology platform.
Enzymatica is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market. The company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ). For more information, visit www.enzymatica.se.
